Biogen receives patent until 2028 for Multiple Sclerosis drug Tecfidera - Reuters

[INCIID News Feed]

<img alt="" height="1" width="1" />
Biogen receives patent until 2028 for Multiple Sclerosis drug Tecfidera
Reuters
Tue Mar 19, 2013 4:14pm EDT. (Reuters) - Biogen Idec Inc said on Tuesday it has been granted a new patent that will help protect the market exclusivity of its multiple sclerosis drug Tecfidera until 2028. The new patent covers the dosing regimen for Tecfidera ...
Biogen Idec Gets New US Patent for Multiple Sclerosis DrugBusinessweek
US Patent Office Grants Patent Claiming Dosing Regimen for TECFIDERA(TM ...MarketWatch (press release)
New data comes from Biogen&#39;s &#39;blockbuster&#39; MS drugTriangle Business Journal (blog)
Zenopa
all 6 news articles &raquo;


More...